NBI-5788 Neurocrine.

Cynthia L, Darlington

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2006

Data sources: Europe PubMed Central

NBI-5788 Neurocrine.

descriptionPublicationkeyboard_double_arrow_right Article 18 Apr 2006 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 6 (issn: 1472-4472,

Copyright policy )

Authors: Cynthia L, Darlington;

pmid: 16044672

NBI-5788 Neurocrine.

- Summary
- Subjects
- Metrics

Abstract

Neurocrine Biosciences is developing NBI-5788, an analog of an immunodominant epitope of myelin basic protein for the potential intravenous treatment of multiple sclerosis. By April 2005, enrollment for phase II trials was complete, with results expected early in 2006.

Related Organizations

University of Otago
New Zealand

Keywords

Neurotransmitter Agents, Clinical Trials, Phase II as Topic, Multiple Sclerosis, Clinical Trials, Phase I as Topic, Animals, Humans, Myelin Basic Protein, Peptide Fragments

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average